Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 11, 2012, Pages

  Rivas Estilla, Ana María ^a   Bryan Marrugo, Owen Lloyd ^a   Trujillo Murillo, Karina ^a   Pérez Ibave, Diana ^a   Charles Niño, Claudia ^b   Pedroza Roldan, Cesar ^b   Ríos Ibarra, Clara ^a   Ramírez Valles, Eda ^a   Ortiz López, Rocío ^a   Islas Carbajal, María Cristina ^c   Nieto, Natalia ^d   Rincón Sánchez, Ana Rosa ^e  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Department of Physiology   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Antioxidants; Glutathione peroxidase; Hepatitis C virus; Oxidative stress; Pyrrolidine dithiocarbamate

Indexed keywords

ACETYLSALICYLIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; VIRUS RNA;

ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION;

ANTIOXIDANTS; ANTIVIRAL AGENTS; ASPIRIN; CELL LINE; CELLS, CULTURED; HEPACIVIRUS; HEPATOCYTES; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; VIRUS REPLICATION;

EID: 84861855852     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00237.2011     Document Type: Article

References (46)

1. Abe Y, Ueda T, Kato T, Kohli Y. [Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C]. Nippon Rinsho 52: 1817-1822, 1994.
2. Barbaro G, Di Lorenzo G, Ribersani M, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, Barbarini G. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 30: 774-782, 1999.
3. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18: 2726-2733, 2009.
4. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295: 306-313, 2006.
5. Bonifazi M, Gallus S, Bosetti C, Polesel J, Serraino D, Talamini R, Negri E, La Vecchia C. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 19: 352-354.
6. Boya P, de la Pena A, Beloqui O, Larrea E, Conchillo M, Castelruiz Y, Civeira MP, Prieto J. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 31: 808-814, 1999.
7. Burra P. Hepatitis C. Semin Liver Dis 29: 53-65, 2009.
8. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31: 456-460, 1993.
9. Cai Y, Appelkvist EL, DePierre JW. Hepatic oxidative stress and related defenses during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. J Biochem Toxicol 10: 87-94, 1995.
10. Chacko EC, Surrun SK, Mubarack Sani TP, Pappachan JM. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J 86: 486-492, 2010.
11. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res 58: 2323-2327, 1998.
12. Chrobot AM, Szaflarska-Szczepanik A, Drewa G. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit 6: 713-718, 2000.
13. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, Pick S, Trzaskos JM. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 91: 11202-11206, 1994.
14. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, Serraino I, Britti D, Mazzullo G, Caputi AP, Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 135: 496-510, 2002.
15. Czyz M, Watala C. [Aspirin-the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organism]. Postepy Hig Med Dosw 59: 105-115, 2005.
16. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Br Med J 339: b4531, 2009.
17. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22: 449-456, 1995.
18. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972, 2005.
19. Ibanez-Hernandez MG, Macias-Islas MA, Zavalza-Gomez AB, Pacheco-Moises FP, Ortiz GG. [The effect of ibuprofen and acetylsalicylic acid on cognitive impairment, total antioxidant power and isoprostane serum]. Gac Med Mex 144: 497-502, 2008.
20. Imlay JA. Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem 77: 755-776, 2008.
21. Kopff M, Kopff A, Kowalczyk E. [The effect of nonsteroidal antiinflammatory drugs on oxidative/antioxidative balance]. Pol Merkur Lekarski 23: 184-187, 2007.
22. Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 24: 1235-1241, 1998.
23. Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E, Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alpha-2b plus ribavirin therapy. J Transl Med 4: 25, 2006.
24. Li K, Prow T, Lemon SM, Beard MR. Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. Hepatology 35: 1237-1246, 2002.
25. Liao CL, Lin YL, Wu BC, Tsao CH, Wang MC, Liu CI, Huang YL, Chen JH, Wang JP, Chen LK. Salicylates inhibit flavivirus replication independently of blocking nuclear factor kappa B activation. J Virol 75: 7828-7839, 2001.
26. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113, 1999.
27. Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res 43: 113-122, 1999.
28. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90: 93-99, 2004.
29. Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 9: 1683-1694, 2007.
30. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 366-375, 2002.
31. Planaguma A, Titos E, Lopez-Parra M, Gaya J, Pueyo G, Arroyo V, Claria J. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor α-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J 16: 1937-1939, 2002.
32. Polat A, Emre MH. Effects of melatonin or acetylsalicylic acid on gastric oxidative stress after bile duct ligation in rats. J Gastroenterol 41: 433-439, 2006.
33. Pomponi M, Di Gioia A, Bria P, Pomponi MF. Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type? Curr Alzheimer Res 5: 422-431, 2008.
34. Pratap R, Pillai K, Khanam R, Islam F, Ahmad SJ, Akhtar M. Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. Hum Exp Toxicol 30: 354-362, 2010.
35. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419: 63-79, 2003.
36. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans 35: 1364-1368, 2007.
37. Rivas-Estilla AM, Svitkin Y, Lopez Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 76: 10637-10653, 2002.
38. Salinas CA, Kwon EM, Fitzgerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL. Use of aspirin and other nonsteroidal anti-inflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172: 578-590, 2010.
39. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 17: 517-521, 1982.
40. Schroder H. Nitric oxide and aspirin: a new mediator for an old drug. Am J Ther 16: 17-23, 2009.
41. Sirven JI. New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin. Mayo Clin Proc 85: 508-511, 2010.
42. Speir E, Yu ZX, Ferrans VJ, Huang ES, Epstein SE. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 83: 210-216, 1998.
43. Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, Bosques-Padilla F, Ramos-Jimenez J, Barrera-Saldana HA, Rojkind M, and Rivas-Estilla AM. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 47: 1462-1472, 2008.
44. Uchide N, Ohyama K, Bessho T, Toyoda H. Effects of mitogenactivated protein kinase inhibitors on tumor necrosis factor-alpha gene expression and apoptosis induction in cultured human fetal membrane chorion cells infected with influenza virus. Intervirology 50: 99-107, 2007.
45. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14: 1093-1099, 1999.
46. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 27: 599-605, 1997.